References
- 1. ADRIANA MUNTEAN AND MIHAI LUCAN. Immunosuppression in kidney transplantation. Clujul Med. 2013; 86(3): 177–180.
- 2. KORBET SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012 Nov. 23(11):1769–76.
- 3. LAURIN LP, GASIM AM, POULTON CJ, HOGAN SL, JENNETTE JC, FALK RJ, et al. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol. 2016; 11(3):386.
- 4. BURDMANN EA, ANDOH TF, YU L, BENNETT WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003; 23(5):465.
- 5. NAIMISSA, ALEKSANDRA KUKLA AND HASSAN N. IBRAHIM. The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors, Arab Journal of Urology (2012) 10, 169–174.
- 6. WILLIAMS D, HARAGSIM L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis. 2006; 13(1):47.
- 7. NAESENS M, KUYPERS DR AND SARWAL M. Calcineurin Inhibitor Nephrotoxicity. Clin J Am SocNephrol. 2009; 4:481–508.
- 8. EKBERG H, TEDESCO-SILVA H, DEMIRBAS A, VÍTKO S, NASHAN B, GÜRKAN A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562.
- 9. [GUIDELINE] Kidney Disease/Improving Global Ooutcomes. KDIGO Clinical Practice Guideline for Glomerulonephritis (GN). Kidney Int. June 2012. 2 suppl 2.
- 10. SCHÖNENBERGER E, EHRICH JH, HALLER H, SCHIFFER M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011: 26(1):18–24.
- 11. FAUL C, DONNELLY M, MERSCHER-GOMEZ S, CHANG YH, FRANZ S, DELFGAAUW J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008: 14(9):931–938.
- 12. ASANUMA K, YANAGIDA-ASANUMA E, FAUL C, TOMINO Y, KIM K, MUNDEL P. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006: 8(5):485–491.
- 13. GIPSON DS, TRACHTMAN H, KASKEL FJ, GREENE TH, RADEVA MK, GASSMAN JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80(8):868.
- 14. HOGG RJ, FRIEDMAN A, GREENE T, RADEVA M, BUDISAVLJEVIC MN, GASSMAN J, et al. Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clin J Am Soc Nephrol. 2013 Feb; 8(2):211–8.
- 15. MONTANÉ B, ABITBOL C, CHANDAR J, JOSÉ STRAUSS, GASTÓN ZILLERUELO. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772.
- 16. PONTICELLI C, RIZZONI G, EDEFONTI A, ALTIERI P, RIVOLTA E, RINALDI S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43(6):1377.
- 17. NIAUDET P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994; 125(6 Pt 1):981.
- 18. LIEBERMAN KV, TEJANI A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996; 7(1):56.
- 19. CHOI MJ, EUSTACE JA, GIMENEZ LF, ATTA MG, SCHEEL PJ, SOTHINATHAN R, et al. Mycophenolate mofetil treatment for primary glomerular diseases.Kidney Int. 2002; 61(3):1098.
- 20. DAY CJ, COCKWELL P, LIPKIN GW, SAVAGE CO, HOWIE AJ, ADU D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002; 17(11):2011.
- 21. DEEGENS JK, ASSMANN KJ, STEENBERGEN EJ, HILBRANDS LB, GERLAG PGG, JANSEN JLJ, et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005; 63:393.
- 22. BANFI G, MORIGGI M, SABADINI E, FELLIN G, D’AMICO G, PONTICELLI C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36:53.
- 23. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int. 1993; 43(3):706.
- 24. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, Hanson P, Mohanty PK, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990; 323(11):693.
- 25. LAURIN LP, GASIM AM, DEREBAIL VK, MCGREGOR JG, KIDD JM, HOGAN SL, et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016; 11:1752.
- 26. KORBET SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:219.
- 27. DIANA TAHERI, ALI CHEHREI, PARGOL SAMANIANPOUR, SHOHREH SADRARHAMI, AMMAR HASSANZADEH KESHTELI AND SHAHRZAD SHAHIDIE. The predictive role of histopathological findings in renal insufficiency and complete remission in a sample of Iranian adults with primary focal segmental glomerulosclerosis. J Res Med Sci. 2010 Jan-Feb; 15(1): 14–19.
- 28. CATTRAN DC, WANG MM, APPEL G, MATALON A, BRIGGS W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol. 2004; 62(6):405.